AU2006259630B2 - Methods of protecting against apoptosis using lipopeptides - Google Patents

Methods of protecting against apoptosis using lipopeptides Download PDF

Info

Publication number
AU2006259630B2
AU2006259630B2 AU2006259630A AU2006259630A AU2006259630B2 AU 2006259630 B2 AU2006259630 B2 AU 2006259630B2 AU 2006259630 A AU2006259630 A AU 2006259630A AU 2006259630 A AU2006259630 A AU 2006259630A AU 2006259630 B2 AU2006259630 B2 AU 2006259630B2
Authority
AU
Australia
Prior art keywords
mice
radiation
cblb601
radioprotectant
irradiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006259630A
Other languages
English (en)
Other versions
AU2006259630A1 (en
Inventor
Andrei Gudkov
Alexander N. Shakhov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Statera Biopharma Inc
Original Assignee
Cleveland Clinic Foundation
Cleveland Biolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation, Cleveland Biolabs Inc filed Critical Cleveland Clinic Foundation
Publication of AU2006259630A1 publication Critical patent/AU2006259630A1/en
Application granted granted Critical
Publication of AU2006259630B2 publication Critical patent/AU2006259630B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2006259630A 2005-06-13 2006-06-13 Methods of protecting against apoptosis using lipopeptides Ceased AU2006259630B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68981005P 2005-06-13 2005-06-13
US60/689,810 2005-06-13
PCT/US2006/022865 WO2006138238A2 (en) 2005-06-13 2006-06-13 Methods of protecting against apoptosis using lipopeptides

Publications (2)

Publication Number Publication Date
AU2006259630A1 AU2006259630A1 (en) 2006-12-28
AU2006259630B2 true AU2006259630B2 (en) 2011-10-27

Family

ID=37571018

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006259630A Ceased AU2006259630B2 (en) 2005-06-13 2006-06-13 Methods of protecting against apoptosis using lipopeptides

Country Status (16)

Country Link
US (4) US8008260B2 (enExample)
EP (2) EP2554181B1 (enExample)
JP (1) JP5000644B2 (enExample)
KR (2) KR20080030566A (enExample)
CN (1) CN101242852B (enExample)
AU (1) AU2006259630B2 (enExample)
BR (1) BRPI0611586A2 (enExample)
CA (1) CA2612102C (enExample)
EA (1) EA014644B1 (enExample)
ES (2) ES2539490T3 (enExample)
IL (1) IL188091A (enExample)
MX (1) MX2007015834A (enExample)
NZ (1) NZ565063A (enExample)
PT (1) PT1904084E (enExample)
WO (1) WO2006138238A2 (enExample)
ZA (1) ZA200800126B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457070B2 (en) 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
CA2654446C (en) 2005-06-07 2014-02-25 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
US8008260B2 (en) 2005-06-13 2011-08-30 Cleveland Clinic Foundation Methods of protecting against apoptosis using lipopeptides
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
KR101493474B1 (ko) * 2007-01-09 2015-02-16 클리브랜드 바이오랩스, 아이엔씨. 조혈 줄기 세포를 증가시키고 이동시키는 방법들
WO2009074569A1 (en) * 2007-12-11 2009-06-18 Bracco International Bv Targeting and therapeutic compounds with a polyproline-comprising spacer and gas-filled microvesicles comprising said compounds
US9150621B2 (en) * 2008-08-28 2015-10-06 The University Of Queensland Mutant bacterial glycoproteins and uses thereof
JP5213961B2 (ja) * 2008-09-18 2013-06-19 日本臓器製薬株式会社 アミノ酸誘導体
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
US8404444B2 (en) * 2009-02-25 2013-03-26 Diacarta Llc Method for predicting the level of damage to cells by measuring free circulating Alu nucleic acid
JP5210405B2 (ja) * 2010-03-17 2013-06-12 日本臓器製薬株式会社 アミノ酸誘導体を含有する医薬及び該誘導体の製造方法
EP2490021A1 (en) 2011-02-18 2012-08-22 Biotempt B.V. Modulators of PRR and GPCR signalling
WO2012125487A1 (en) * 2011-03-11 2012-09-20 Omni Bio Pharmaceutical, Inc. Compositions, methods and uses for radioprotectants
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
JP5686841B2 (ja) * 2013-04-26 2015-03-18 フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 損傷しまたは傷害を受けた組織または臓器の内皮／上皮再生用医薬の製造のための、幹細胞由来微小胞（ｍｖ）の使用ならびにインビトロおよびインビボでの関連した方法
US20160287553A1 (en) 2013-11-22 2016-10-06 Deutsches Krebsforschungszentrum Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
WO2016073733A1 (en) * 2014-11-06 2016-05-12 Cleveland Biolabs, Inc. Methods of treating cancer using lipopeptides
CN112851755B (zh) * 2021-01-13 2023-09-01 中国人民解放军军事科学院军事医学研究院 一种线性脂肽化合物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449761A (en) * 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000330B1 (de) 1977-06-20 1981-08-05 Ciba-Geigy Ag Lipopeptide, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Präparate
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
EP0604945A1 (en) 1992-12-28 1994-07-06 Takeda Chemical Industries, Ltd. TAN-1511, its derivatives, production and use thereof
AU666789B2 (en) * 1992-12-28 1996-02-22 Takeda Chemical Industries Ltd. 2-amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
WO1995012675A1 (en) 1993-11-04 1995-05-11 Cytoclonal Pharmaceutics, Inc. A fusion protein and method for making and using same
WO1999035162A1 (en) 1998-01-07 1999-07-15 Jenner Biotherapies, Inc. Therapeutic liposome-encapsulated immunomodulators
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
DE19822820A1 (de) 1998-05-20 1999-11-25 Biotechnolog Forschung Gmbh Pharmazeutisches Präparat zur Wundbehandlung
US20030170249A1 (en) * 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
AU4972200A (en) * 1999-04-26 2000-11-10 Center For Molecular Medicine And Immunology Use of antioxidants to mitigate radioimmunotherapy-induced radiation toxicity
EP1964854A2 (en) * 1999-10-27 2008-09-03 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions
DE10048840A1 (de) * 2000-10-02 2002-04-11 Biotechnolog Forschung Gmbh Verwendung von Lipopeptiden oder Lipoproteinen zur Behandlung von Lungeninfektionen und -tumoren
CN102302493B (zh) 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
EP1490106B1 (de) 2002-04-04 2008-05-28 Helmholtz-Zentrum für Infektionsforschung GmbH Verwendung eines lipopeptids oder lipoproteins als adjuvans bei therapeutischer oder prophylaktischer vakzinierung
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
US20040259790A1 (en) * 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
WO2005030133A2 (en) * 2003-09-22 2005-04-07 Yale University Treatment with agonists of toll-like receptors
EP1706133B1 (en) * 2003-12-02 2010-10-06 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
US20060039895A1 (en) * 2004-02-28 2006-02-23 Large Scale Biology Corporation Ex-vivo rescue of hematopoietic stem cells after lethal irradiation
US8008260B2 (en) 2005-06-13 2011-08-30 Cleveland Clinic Foundation Methods of protecting against apoptosis using lipopeptides
KR101493474B1 (ko) 2007-01-09 2015-02-16 클리브랜드 바이오랩스, 아이엔씨. 조혈 줄기 세포를 증가시키고 이동시키는 방법들

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449761A (en) * 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs

Also Published As

Publication number Publication date
US9006183B2 (en) 2015-04-14
US8524668B2 (en) 2013-09-03
EA014644B1 (ru) 2010-12-30
EP1904084B1 (en) 2013-04-24
EA200702510A1 (ru) 2008-06-30
KR20140041874A (ko) 2014-04-04
EP2554181B1 (en) 2015-03-18
JP2008543847A (ja) 2008-12-04
KR101604799B1 (ko) 2016-03-28
CN101242852A (zh) 2008-08-13
US9381225B2 (en) 2016-07-05
JP5000644B2 (ja) 2012-08-15
US20110237507A1 (en) 2011-09-29
IL188091A0 (en) 2008-03-20
US20150306168A1 (en) 2015-10-29
EP2554181A2 (en) 2013-02-06
KR20080030566A (ko) 2008-04-04
WO2006138238A3 (en) 2007-07-19
ZA200800126B (en) 2009-10-28
ES2421447T3 (es) 2013-09-02
EP1904084A2 (en) 2008-04-02
CA2612102A1 (en) 2006-12-28
EP1904084A4 (en) 2012-03-21
US20090214467A1 (en) 2009-08-27
MX2007015834A (es) 2008-09-15
BRPI0611586A2 (pt) 2010-09-21
HK1123495A1 (en) 2009-06-19
HK1181684A1 (en) 2013-11-15
NZ565063A (en) 2011-04-29
US20140045750A1 (en) 2014-02-13
AU2006259630A1 (en) 2006-12-28
EP2554181A3 (en) 2013-03-13
CA2612102C (en) 2016-02-09
US8008260B2 (en) 2011-08-30
ES2539490T3 (es) 2015-07-01
IL188091A (en) 2014-06-30
PT1904084E (pt) 2013-07-22
CN101242852B (zh) 2012-10-10
WO2006138238A2 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
US9381225B2 (en) Methods of protecting against apoptosis using lipopeptides
US10406206B2 (en) Protection against stress-mediated damage from ionizing radiation
US20190381139A1 (en) Protection against stress-mediated damage from ionizing radiation
HK1181684B (en) Methods of protecting against apoptosis using lipopeptides
WO2005056054A2 (en) METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
HK1123495B (en) Methods of protecting against apoptosis using lipopeptides

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
TH Corrigenda

Free format text: IN VOL 24, NO 20, PAGE(S) 2200 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN, PATENTS CEASED OR EXPIRED - 2006 DELETE ALL REFERENCE TO 2006259630.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired